Oncology Institute(The) EBIT

The latest EBIT for TOI is $-26M as of June 2026. That compares with $-51M in the prior-year period — up 48.9% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Oncology Institute(The)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, TOI's EBIT moved from $-51M to $-26M — a 48.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oncology Institute(The)'s operating scale or balance-sheet position.

Against its sector companies, TOI currently prints $-26M for EBIT, while the sector average sits near $-63M. That is roughly 58.3% above the sector mean. Large gaps often invite a closer look at Oncology Institute(The)'s growth, margins, and balance sheet.

A EBIT figure of $-26M for TOI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting TOI's EBIT ($-26M), review year-over-year change from $-51M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.